Small Pharmaceuticals

Concord Biotech Ltd.

CONCORDBIO

Market Cap
₹14,067 Cr.
P/E
53.91

Concord Biotech Ltd.

  • Concord Biotech
  • Biocon
  • Guj. Themis Biosyn
  • TJI Pharma - API & CRAMS

FAQs on Concord Biotech Ltd. Shareprice

Concord Biotech has given lower returns compared to its competitors.
Concord Biotech has grown at ~-11.07% over the last 2yrs while peers have grown at a median rate of 18.0%

Concord Biotech is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA.
Latest PE of Concord Biotech is 53.91, while 3 year average PE is 53.6.
Also latest EV/EBITDA of Concord Biotech is 38.25 while 3yr average is 38.94.

View FAQ's On Business

Growth Table

  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn

Balance Sheet

  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn

Cash Flow

  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn

Quarterly Results

  • Concord Biotech Ltd.
  • Biocon
  • Guj. Themis Biosyn

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Concord Biotech Ltd. Financials

Balance sheet of Concord Biotech is strong.
It shouldn't have solvency or liquidity issues.

The net debt of Concord Biotech is decreasing.
Latest net debt of Concord Biotech is -₹27.14 Crs as of Mar-26.
This is less than Mar-25 when it was -₹1.97 Crs.

The profit is oscillating.
The profit of Concord Biotech is ₹261 Crs for Mar 2026, ₹372 Crs for Mar 2025 and ₹308 Crs for Mar 2024

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Concord Biotech latest dividend payout ratio is 30.27% and 3yr average dividend payout ratio is 30.03%

Companies resources are allocated to majorly unproductive assets like Cash & Short Term Investments, Inventory

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech